This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Desbois, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desbois, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2008, p. 1545-1548, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01284-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors{triangledown}

Delphine Desbois,1 Bénédicte Roquebert,1 Gilles Peytavin,2 Florence Damond,1 Gilles Collin,1 Antoine Bénard,5 Pauline Campa,4 Sophie Matheron,3 Geneviève Chêne,5 Françoise Brun-Vézinet,1 Diane Descamps,1* for the French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)

Laboratoire de Virologie, Service de Microbiologie, Hôpital Bichat-Claude Bernard, Paris, France,1 Laboratoire de Toxicologie, Service de Pharmacie, Hôpital Bichat-Claude Bernard, Paris, France,2 Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France,3 Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France,4 ISPED, Université Victor Segalen Bordeaux 2, INSERM U593, Bordeaux, France5

Received 4 October 2007/ Returned for modification 19 November 2007/ Accepted 14 January 2008

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.

* Corresponding author. Mailing address: Laboratoire de Virologie, Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France. Phone: 33 1 40 25 61 54. Fax: 33 1 40 25 67 69. E-mail: diane.descamps{at}bch.aphp.fr

{triangledown} Published ahead of print on 28 January 2008.

Antimicrobial Agents and Chemotherapy, April 2008, p. 1545-1548, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01284-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Descamps, D., Lambert-Niclot, S., Marcelin, A.-G., Peytavin, G., Roquebert, B., Katlama, C., Yeni, P., Felices, M., Calvez, V., Brun-Vezinet, F. (2009). Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother 63: 585-592 [Abstract] [Full Text]  
  • Roquebert, B., Damond, F., Collin, G., Matheron, S., Peytavin, G., Benard, A., Campa, P., Chene, G., Brun-Vezinet, F., Descamps, D., on behalf of the French ANRS HIV-2 Cohort (ANRS CO, (2008). HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 62: 914-920 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»